Ibuprofen vs. emphysema? UNMC leads national study

by Vicky Cerino, UNMC public relations | November 12, 2013

Image with caption: Stephen Rennard, M.D.

Stephen Rennard, M.D.

UNMC will lead a clinical research study that will evaluate if a common, over-the-counter drug has potential to reverse the devastating effects of emphysema.

The phase II, three-year study funded for $4.4 million by the National Institutes of Health (NIH) National Heart, Lung and Blood Institute, will look at whether ibuprofen can reduce inflammation in the lungs. Ibuprofen is a non-steroidal, anti-inflammatory drug commonly used to treat pain and swelling.

"Emphysema has been regarded as an irreversible type of chronic obstructive pulmonary disease (COPD) involving damage to the air sacs in the lungs. But, in fact, it may be reversible," said Stephen Rennard, M.D., Larson Professor of Medicine in the Pulmonary and Critical Care Medicine Section of the Department of Internal Medicine.

Dr. Rennard said current treatments -- medication, rehabilitation, and sometimes surgery -- can help with symptoms and can reduce exacerbations, but nothing yet can reverse the course of the disease.

"Recent studies support the concept that the ability of the lung to repair damage is suppressed. If you can remove the suppression, then maybe lungs can be repaired. This would be important and entirely new," said Dr. Rennard, principal investigator of the study and a recognized expert in COPD.

"Recent evidence indicates lung repair processes are diminished in COPD, partly due to increased levels of prostaglandin E. We know that ibuprofen blocks the production of prostaglandins. We want to know if it can block prostaglandins in the lung," Dr. Rennard said.

Study participants will take 600 milligrams of ibuprofen or a placebo three times a day. Researchers will measure inflammation and use biochemical techniques to determine the extent of lung repair that occurs. They also will compare previous CT scans and pulmonary function tests with results obtained before and after treatment.

If it works, researchers will seek approval to conduct a larger clinical study in patients.

UNMC will coordinate the study and analyze the data. Four other medical centers also are involved in the study. They will recruit 140 patients with emphysema who participated in a previous large NIH emphysema study. The medical centers are National Jewish Health in Denver, Brigham and Women's Hospital in Boston, Temple University in Philadelphia and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

Comments

Fill out the following and your comment will post once it has been approved.

Thank you, your comment will appear below once it has been approved.

Bob
August 14, 2014 at 1:19 PM

Is it 600 milligrams 3 x a day or 600 milligrams a day? Bramsay, you said you were taking 600 mg "TID" is that per day or per dose?

MackK
August 04, 2014 at 2:04 PM

Isn't 1800 milligrams a day dangerous to some organ or other? Liver?

Darlene
July 19, 2014 at 8:59 PM

Bramsay: also find this info: http://en.wikipedia.org/wiki/Acute_pericarditis and it states: The preferred NSAID is ibuprofen because of rare side effects, better effect on coronary flow, and larger dose range

Darlene
July 19, 2014 at 8:53 PM

Bramsay: I just am reading about ibuprofen for the first time. Are you still using it? I am searching for that one thing that the doctors won't tell us.

bramsay
April 08, 2014 at 7:49 AM

I have advanced COPD diagnosed several years ago. I have been taking ibuprofen 200 mg TID since early March 2014 (about five weeks now). I have found significant reduction in respiratory mucus which has meant better breathing and motility for me. Now I find that ibuprofen is linked to increased incidence of coronary thrombotic episodes. Don't know what to do now. Ya' can't win can ya'.

Ernie Laczo
November 18, 2013 at 8:42 PM

I hope there is Help for us I more than willing to try it Kewldesign@hotmail.com Good luck with hope

caroline gillissen
November 13, 2013 at 3:58 AM

Will people with Alpha-1 Antitrypsin Deficiency be excluded from this study of NSAID use to treat emphysema? NSAID's are thought to increase liver injury in Alpha-1 http://alpha-1foundation.org/alpha-1-and-liver-disease/liver-disease-qa/ .

Myron L. Toews, PhD
November 12, 2013 at 12:20 PM

Dr. Rennard was UNMC's first Scientist Laureate. His selection by NIH to lead this new national study provides additional evidence that he is indeed a scientist worthy of laurels! Let's hope the treatment does in fact work!